Soligenix (SNGX) Current Deferred Revenue (2018 - 2022)
Soligenix's (SNGX) quarterly Current Deferred Revenue came in at $100000.0 in Q3 2022, little changed on a QoQ basis from $100000.0 in Q2 2022.
Soligenix (SNGX) Current Deferred Revenue (2018 - 2022) Analysis & Trends
Soligenix (SNGX) has 3 years of Current Deferred Revenue data on file, last reported at $100000.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Soligenix | 6.45 Mn | 6.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 100,000.00 |
| Jun 30, 2022 | 100,000.00 |
| Sep 30, 2019 | 34,988.00 |
| Jun 30, 2019 | 69,976.00 |
| Mar 31, 2019 | 104,963.00 |
| Sep 30, 2018 | 259,862.00 |
| Jun 30, 2018 | 56,692.00 |